(Q35108534)

6 August 2017

title

Insights and advances in chronic urticaria: a Canadian perspective (English)

1 reference

6 August 2017

1 reference

1 reference

Stephen Daniel Betschel

10

object named as

Stephen Betschel

1 reference

6 August 2017

4

Charles Lynde

1 reference

6 August 2017

7

Moshe Ben-Shoshan

1 reference

6 August 2017

18

F Estelle R Simons

1 reference

6 August 2017

Gordon Sussman

1

1 reference

6 August 2017

Jacques Hébert

2

1 reference

6 August 2017

Wayne Gulliver

3

1 reference

6 August 2017

Susan Waserman

5

1 reference

6 August 2017

Amin Kanani

6

1 reference

6 August 2017

Spencer Horemans

8

1 reference

6 August 2017

Carly Barron

9

1 reference

6 August 2017

William H Yang

11

1 reference

6 August 2017

Jan Dutz

12

1 reference

6 August 2017

Neil Shear

13

1 reference

6 August 2017

Gina Lacuesta

14

1 reference

6 August 2017

Peter Vadas

15

1 reference

6 August 2017

Kenneth Kobayashi

16

1 reference

6 August 2017

Hermenio Lima

17

1 reference

6 August 2017

publication date

11 February 2015

1 reference

Allergy, Asthma & Clinical Immunology

6 August 2017

published in

1 reference

6 August 2017

volume

11

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

7

1 reference

Creative Commons Attribution 4.0 International

6 August 2017

copyright license

start time

11 February 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13223-015-0072-2

0 references

cites work

Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

The diagnosis and management of acute and chronic urticaria: 2014 update.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing?

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Development, validation, and initial results of the Angioedema Activity Score

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Psychosocial factors and chronic spontaneous urticaria: a systematic review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Histamine H2-receptor antagonists for urticaria

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Histamine and H1-antihistamines: celebrating a century of progress

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Second-generation H1-antihistamines in chronic urticaria: an evidence-based review

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Axis I and Axis II diagnoses in patients with chronic idiopathic urticaria

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Real-life experiences with omalizumab for the treatment of chronic urticaria.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity.

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL).

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4336710

Chronic idiopathic urticaria (CIU) is no longer idiopathic: time for an update

27 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FS13223-015-0072-2

A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25705232

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H 1 Antihistamines: A Randomized, Placebo-Controlled Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25705232

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S13223-015-0072-2

1 reference

Dimensions Publication ID

6 August 2017

0 references

1 reference

6 August 2017

1 reference